HOME >> BIOLOGY >> NEWS
Equine cloning may shed light on human cancer causes

mong horses is so low.

In July 2001, however, the team supplemented the amount of calcium in the implanted clones. "We increased the calcium in the medium holding the embryos and saw a seven-fold increase in our week two pregnancy rates," Woods said. "We produced 19 pregnancies; the first baby has been born, and two more pregnancies are in the advanced stages."

The team concluded that the increase in calcium within the implanted clone cells directly impacted the speed of cell division. Understanding the role of calcium in equine cell activity was a direct result of work conducted by Cancer2. Cancer2 gifted the intellectual property to UI.

According to existing research, the amount of intracellular calcium is higher than normal in humans with metastasizing cancer. According to Woods' research, the amount of intracellular calcium is below normal in horses. Within Cancer2, Woods and his team have discovered a chemical that suppresses intracellular calcium. Abnormally high intracellular calcium is a root cause of abnormally high cell activity in aged humans.

"There are electrifying similarities between cancer metastasis and embryo division," said Woods. He said he is working toward critical testing of the effects of deficiencies in the suppressor in human clinical trials. "We've identified a suppressor of intracellular calcium and believe its deficiency is the root cause of abnormally high intracellular calcium."

Woods established the Northwest Equine Reproduction Laboratory on the UI campus in 1986. He had come full circle, having completed pre-veterinary courses at the UI in 1974. A few years later, he earned the D.V.M. degree from Colorado State University.

Woods returned to the Northwest briefly to practice veterinary medicine then moved east to complete a residency in large animal reproduction at the University of Pennsylvania under R. M. Kenney. Next, at the University of Wisconsin, he became a student of O. J. Ginther, and complete
'"/>

Contact: Kathy Barnard
kbarnard@uidaho.edu
208-885-6291
University of Idaho
29-May-2003


Page: 1 2 3

Related biology news :

1. Equine clonings triple play sheds light on calcium, cell signaling, human disease
2. Malignant cancer cells generate mice through cloning
3. Stem-cell research and reproductive cloning laws should be separate
4. Therapeutic cloning no longer a dream, says scientist who produced first cloned embryonic stem cell
5. Why does cloning create abnormalities? Scientists take a step towards finding out
6. Therapeutic cloning may be permitted at Newcastle University
7. Landmark conference for United Nations on human cloning and stem cell research
8. Scientists develop new cloning technique that dramatically shortens the search for genes
9. Advances in equine cloning may aid insight into human diseases
10. International scientific body calls for ban on human reproductive cloning
11. Research shows therapeutic cloning can cure Parkinsons-like disease in mice

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Equine cloning may shed light human cancer causes

(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... 21, 2015 Imagine being able ... and those of others. Being able to read faces ... read people to anticipate their thoughts and actions like ... and feelings to create unique abstract paintings and video, ... Get inside a first-person-shooter as it creates action, dialog, ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
Cached News: